Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet

2026-02-23 13:57:30 ET

Baker Bros. Advisors reported a buy of 2,005,813 Kymera Therapeutics (NASDAQ:KYMR) shares in its February 17, 2026, SEC filing, an estimated $135.45 million trade based on quarterly average pricing.

According to a February 17, 2026 SEC filing , Baker Bros. increased its holding in Kymera Therapeutics (NASDAQ:KYMR) by 2,005,813 shares. The estimated trade value was $135.45 million, based on the average closing price during the fourth quarter of 2025. The fund’s quarter-end position value in Kymera Therapeutics rose by $297.15 million, a change that includes both trading activity and share price appreciation.

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on leveraging targeted protein degradation to address serious diseases with high unmet need. The company’s pipeline includes programs in immunology, oncology, and fibrosis, supported by a growing portfolio of proprietary technologies. Strategic emphasis on first-in-class therapies and partnerships with leading industry players position Kymera as an innovator in the protein degradation space.

Continue reading